Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.

Molecular cancer therapeutics - 1 Jul 2010

Augustine Christina K, Toshimitsu Hiroaki, Jung Sin-Ho, Zipfel Patricia A, Yoo Jin S, Yoshimoto Yasunori, Selim M Angelica, Burchette James, Beasley Georgia M, McMahon Nicole, Padussis James, Pruitt Scott K, Ali-Osman Francis, Tyler Douglas S

Abstract excerpt

Melanoma responds poorly to standard chemotherapy due to its intrinsic chemoresistance. Multiple genetic and molecular defects, including an activating mutation in the BRaf kinase gene, are associated with melanoma, and the resulting alterations in signal transduction pathways regulating proliferation and apoptosis are thought to contribute to its chemoresistance. Sorafenib, a multikinase inhibitor that targets...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Butadienes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dacarbazine

Share to Melphalan

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Rats, Nude

Share to Sorafenib

Share to Temozolomide

Source

Identifiers

PMID: 20571072
DOI: 10.1158/1535-7163.MCT-10-0073

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.PMID 20571072Read ↗

A phase II trial of sorafenib in metastatic melanoma with tissue correlates.Semantic proximity Read ↗

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.Semantic proximity Read ↗

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.Semantic proximity Read ↗

Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.Semantic proximity Read ↗

Specifically targeting ERK1 or ERK2 kills Melanoma cellsSemantic proximity Read ↗

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.Semantic proximity Read ↗

Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.Semantic proximity Read ↗

Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.Semantic proximity Read ↗

Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.Semantic proximity Read ↗

The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.Semantic proximity Read ↗

The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.